Intranasal Oxytocin for Managing Agitation in a Patient of Mixed Dementia With Multiple Pathologies, Particularly With a History of Repetitive Head Injuries
Journal of Geriatric Psychiatry and Neurology
Published online on September 19, 2025
Abstract
Journal of Geriatric Psychiatry and Neurology, Volume 39, Issue 4, Page 426-430, July 2026.
BackgroundAgitation is common in persons living with dementia (major neurocognitive disorder) and worsens with disease progression. Brexpiprazole is the sole FDA-approved drug for agitation in persons with Alzheimer’s dementia, but requires daily dosing ...
BackgroundAgitation is common in persons living with dementia (major neurocognitive disorder) and worsens with disease progression. Brexpiprazole is the sole FDA-approved drug for agitation in persons with Alzheimer’s dementia, but requires daily dosing ...